Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CADx gets US nod for two new Second Look products:

This article was originally published in Clinica

Executive Summary

CADx Systems has received US FDA approval for two new computer-aided detection (CAD) systems for use with mammography. The Second Look Digital is aimed purely at highlighting suspicious areas on images taken using digital mammography, whilst the Second Look AD is a hybrid system able to analyse both traditional film-based or digital images. The approval allows both systems to process images from GE Medical Systems' Senographe 2000D full field digital mammography system. The Beavercreek, Ohio firm told Clinica it is also working on getting approval for integration of the products with imaging systems made by Fischer Imaging and Hologic. The new CAD systems complement the firm's Second Look CAD for film-based mammography, which is already on the market.

You may also be interested in...



Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT063444

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel